Inhibition of S-phase kinase-associated protein 2-mediated p27 degradation suppresses tumorigenesis and the progression of hepatocellular carcinoma

MING QI1, DONGMEI LIU2, SHUHONG ZHANG1, PEIXIN HU1 and TAN SANG3

Departments of 1Digestive System, 2Transfusion Center and 3Hematology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China

Received January 2, 2014; Accepted October 1, 2014

DOI: 10.3892/mmr.2015.3156

Abstract. In order to determine the protein expression of S-phase kinase-associated protein 2 (Skp2) and p27kip1, and to evaluate their possible prognostic values in malignant liver cancer, tissue samples from 50 patients and 40 controls were assessed and analyzed by immunohistochemistry and western blot analysis. Positive expression of Skp2 was observed in 35 (70.0%) of the hepatocellular carcinoma samples; however, the positive expression of p27kip1 was observed in 6 (15.0%) of the hepatocellular carcinoma samples. The expression of Skp2 was significantly negatively correlated with the expression of p27kip1 (P<0.01). The results from Annexin V-propidium iodide staining and MTT assays indicated that interference of Skp2 significantly induced apoptosis and inhibited the proliferation of SSMC-7721 cells. In addition, the levels of endogenous p27 increased in the HepG2 and SSMC-7721 cells following transfection with siRNA specific to Skp2, suggesting that the Skp2-mediated degradation of p27kip1 was important in the proliferation of tumor cells. The present study, therefore, provided a molecular reference for the treatment of liver cancer.

Introduction

Liver cancer is a malignant disease, which forms on the surface or within the liver, including in blood vessels or the bile duct (1-3). It is one of the most common types of solid tumor worldwide and is the third leading cause of cancer-associated mortality (4). Primary liver cancer is the most common type of malignant tumor, with poor prognosis and a high mortality rate (5,6). It currently leads to 360,000 incident cases and the mortality of 350,000 individuals annually in China (7). The incidence and mortality rates of hepatocellular carcinoma in China account for 40-45% and 18.8% of the patients with liver cancer worldwide, respectively. Untreated patients with advanced disease usually survive <6 months (8) and, in 25 randomized clinical trials, the 1 and 2 year survival rates of untreated patients were between 10 and 72% and between 8 and 50%, respectively (8). Thus, liver cancer is one of the major diseases affecting health.

Tumors occur in several diseases and result from disordered cell cycle regulation or loss of control over cell division. The unchecked cells may eventually form malignancies, with the activation of oncogenes or inhibition of tumor suppressor genes (9,10).

The cyclin kinase inhibitor p27kip1 is a cell-cycle regulatory protein, which is one of the most important regulators of the cell cycle (11). It interacts with cyclin-dependent kinase (CDK)2 and CDK4 to inhibit cell cycle progression at the G1 phase and is also the checkpoint of the G1-S phase transition (12,13). The degradation of p27kip1 is dependent on the ubiquitin-proteasome pathway. Thus is generally triggered by phosphorylation of conserved threonine (Thr187) and subsequent ubiquitination by Skp, Cullin and F-box (SCF) complexes, and is required for cell division (14,15). The ubiquitin-proteasome system is mediated by three enzymes, ubiquitin-activating enzyme, ubiquitin-conjugating enzyme and E3 ubiquitin ligase. S-phase kinase-associated protein 2 (Skp2) is one type of E3 ubiquitin ligase for recruiting a specific substrate and determining their specificity (16). Thus, Skp2 acts as an adaptor of the SCF-Skp2 complex and recognizes phosphorylated substrates, including p27kip1 and p21.

Skp2 acts as an oncogene and overexpression of Skp2 is frequently observed in several types of human tumor, including lymphoma, prostate cancer, melanoma, nasopharyngeal carcinoma, pancreatic cancer and breast carcinomas, which promotes the progression and metastasis of human cancer (17-20). By comparison, p27kip1, a tumor inhibitor protein, usually inhibits the progression of human cancer. In the present study, the role of the Skp2-p27 pathway in the progression of human liver cancer was investigated and the underlying mechanism was examined. Clarification of the process and progression of carcinogenesis in liver tissues
may provide novel targets for the effective prevention of liver cancer.

Materials and methods

Liver cancer cell lines. The HepG2 and SMMC-7721 liver cancer cell lines (American Type Culture Collection, Manassas, VA, USA) were maintained in the laboratory at Jinan Central Hospital Affiliated to Shandong University (Shandong, China) and were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (HyClone, GE Healthcare Life Sciences, Little Chalfont, UK), 1% penicillin and 1% streptomycin (Gibco-BRL, Invitrogen Life Technologies, Carlsbad, CA, USA).

Small interfering (si)RNA and antibodies. The cells were planted in 48-well plates and subsequent to a 24-h resting period, the Skp2 p45 siRNA and scramble siRNA was transfected with Lipofectamine 2000 (Invitrogen Life Technologies). Following 8 h of transfection, the DMEM medium was replaced and the lysates were prepared subsequent to transfection for 48 h. The Skp2 p45 siRNA was purchased from Santa Cruz Biotechnology, Inc. (sc-36499; Dallas, TX, USA) and scramble siRNA was synthesized by Shanghai Jima Company (Shanghai, China). Rabbit polyclonal immunoglobulin G (IgG) Skp2 p45 antibody (200 µg/ml; sc-7164), mouse monoclonal IgG, p27 antibody (200 µg/ml; sc-53906) and mouse monoclonal IgG, β-actin (AC-15) antibody (100 µg/ml; sc-69879), as well as horseradish peroxidase-conjugated goat anti-mouse secondary antibody (sc-2005) were all obtained from Santa Cruz Biotechnology, Inc.

Histology and immunohistochemistry. Liver tissue samples were obtained from Jinan Central Hospital Affiliated to Shandong University. The subjects included 50 cases of hepatocellular carcinoma and 40 paratumor tissues with an average age of 58±13 years. The subjects were recruited from March 2011 to December 2013. The specimens were obtained during surgery. There were 52 male and 38 female patients during the experiment. Written informed consent was also obtained from the patients' families. The study was approved by the ethics committee of Jinan Central Hospital Affiliated to Shandong University (Jinan, China). The liver tissues were fixed in neutral buffered paraformaldehyde and processed for hematoxylin and eosin (H&E) staining. Immunohistochemical staining was performed, as previously described (21,22). Briefly, the paraffin-embedded sections were dewaxed, rehydrated, inhibited and incubated overnight with the primary antibodies (anti-p27 and anti-Skp2). Subsequently, the samples were incubated with goat anti-mouse and goat anti-rabbit secondary antibodies (Santa Cruz Biotechnology) for 1 h. The slides were stained, dehydrated and cleared and the stained slides were mounted in Permount and visualized using a Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan). Images were captured using an FE330 digital camera (Olympus Corporation, Tokyo, Japan), which was attached to the microscope.

Western blot analysis. The whole cell extracts were prepared and separated by PAGE, as previously described (23-25) using buffer and gel obtained from Shanghai Qcbio Science and Technologies Co., Ltd. (Shanghai, China) and the machine (Mini-Protein® Tetra Cell) from obtained from Bio-Rad (Hercules, CA, USA). The proteins of the sample were separated using gel electrophoresis and were subsequently transferred to a polyvinylidine difluoride membrane (Millipore, Billerica, MA, USA). Subsequently, blocking of non-specific binding was achieved by placing the membrane in a solution of 5% bovine serum albumin. Following blocking, a dilute solution of the appropriate primary antibody was incubated with the membrane at 4°C overnight. The antibodies used were as follows: Anti-p27, anti-Skp2, anti-β-actin and horseradish peroxidase-conjugated goat anti-mouse secondary antibody.

MTT assay. An MTT assay was performed, as described previously (26-28). The cells (5x10^4) were seeded into 48-well plates. Following culture for 24, 48 or 72 h, the plates were read on a microplate reader (Varioskan Flash Multimode Reader; Thermo Fisher Scientific, Waltham, MA, USA) at a test wavelength of 490 nm and a reference wavelength of 570 nm.

Immunoprecipitation. Immunoprecipitation was performed, as previously described (29-31). The cells were lysed and the sample was passed over beads alone or bound to a relevant antibody to absorb any proteins that non-specifically bind to the immunoprecipitation components. For immunoprecipitation analysis, the samples were immunoprecipitated with mouse monoclonal hemagglutinin (HA)-tag antibodies

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Sample no.</th>
<th>Skp2</th>
<th>Positive rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular carcinoma</td>
<td>50</td>
<td>15</td>
<td>35</td>
</tr>
<tr>
<td>Paratumor</td>
<td>40</td>
<td>34</td>
<td>6</td>
</tr>
</tbody>
</table>

*P<0.01 compared with paratumor tissues. Skp2, S-phase kinase-associated protein 2.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Sample no.</th>
<th>p27kip1</th>
<th>Positive rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular carcinoma</td>
<td>50</td>
<td>42</td>
<td>8</td>
</tr>
<tr>
<td>Paratumor</td>
<td>40</td>
<td>4</td>
<td>36</td>
</tr>
</tbody>
</table>

*P<0.01 compared with paratumor tissues.
The immuno-complexes were separated by SDS-PAGE and treated with the secondary antibody. The complexes of Skp2 or ubiquitin with p27<sup>kip1</sup> were determined by immunoprecipitating the mouse monoclonal anti-Flag antibody (AF519; Beyotime Institute of Biotechnology, Haimen, China) and normalized to the quantity of antibodies. To assess the specificity of the primary antibodies, negative controls were used, in which the antibodies used to immunoprecipitate were incubated for 2 h at room temperature with the respective immunogen peptide.

**FACS analysis.** Cell apoptosis rate was determined by Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) (Hangzhou Lianke Biology Technology Limited Company, Hangzhou, China) staining. The one-step staining procedure was selected, which takes only 10 min to perform. Detection was analyzed by flow cytometry (FC 500; Beckman Coulter, Brea, CA, USA), which differentiates between apoptosis and necrosis following Annexin V-FITC and PI staining.

**Statistical analysis.** Student's t-test was used to evaluate statistical significance. Data were analyzed using SPSS 19.0 (IBM SPSS, Armonk, NY, USA) Data are expressed as the mean ± standard deviation. P<0.05 were considered to indicate a statistically significant difference.
Results

Positive Skp2 staining is observed in the majority of liver cancer tissues. In the present study, 90 registered patients were obtained from the database of Jinan Central Hospital Affiliated to Shandong University. As shown in Fig. 1, H&E staining of the samples of paratumor liver tissue and hepatocellular carcinoma tissue was compared with normal liver tissues. It is reported that the Skp2-p27kip1 signaling pathway is closely associated with cancer (32,33). In the present study, the expression levels of Skp2 and p27kip1 were detected by immunohistochemical analyses in the paratumor and hepatocellular carcinoma tissues. The results revealed that the positive brown staining for Skp2 was predominantly observed in the nuclei with occasional cytoplasmic expression (Fig. 2). Compared with the immunostaining of the paratumor tissues, nuclear and cytoplasmic localization of Skp2 was observed in the majority of the examined samples in the patients with hepatocellular carcinoma (Table I) with 70.0% of the malignant tumors demonstrating varying levels of positive immunostaining. A significant difference was observed between the two groups (P<0.01).

Localization of Skp2 detected by western blot analysis. In order to confirm the localization of Skp2 in SSMC 7721 and HepG2 cells, cytoplasmic and nucleic proteins were prepared and western blot analysis was performed. As shown in Fig. 3, the results revealed that the majority of Skp2 was located in the nuclei of the cells; although there was low expression detected in the cytoplasm.

Skp2 is degraded by the ubiquitin-proteasome pathway regulated by Skp2. In order to examine whether the degradation of p27kip1 is regulated by Skp2, 293T cells, which expressed HA-Skp2, Flag-p27 and ubiquitin together were used. After 48 h, a co-immunoprecipitation assay was performed and the data demonstrated that the K48-linked p27kip1 increased and the K63-linked p27kip1 decreased. The total quantity of ubiquitinated p27kip1 was also downregulated (Fig. 4). Taken together, these data demonstrated that p27kip1 was degraded by the ubiquitin-proteasome pathway, which was mediated by the Skp2 complex.

Interference of Skp2 induces the apoptosis and inhibits the proliferation of SSMC-7721 cells. Skp2 is an oncogene, which is highly expressed in tumor cells. The present study investigated whether interference of Skp2 with specific siRNA induced the apoptosis of liver cancer cells or promoted liver cancer cell death. As shown in Fig. 5, the apoptotic rates of the SSMC-7721 cells transfected with Skp2-siRNA were significantly higher compared with the control cells (P<0.01).
In the MTT assay (Fig. 5C), the optical density at 490 nm in the cells transfected with Skp2 siRNA were significantly lower compared with that of the control cells (P<0.05 and P<0.01). This was consistent with the results observed by fluorescence-activated cell sorting (FACS), suggesting that the proliferation of cancer cells was inhibited following transfection with Skp2-siRNA.

Interference of the expression of Skp2 increases the expression of p27kip1. The present study demonstrated that interference of Skp2 induced apoptosis and inhibited proliferation of the SSMC-7721 cells. In order to further examine the mechanism involved and clarify the association with the expression of p27kip1, the expression of p27kip1 was examined by western blot analysis. As shown in Fig. 6, following depletion of the expression of endogenous Skp2 by RNA interference, the levels of endogenous p27kip1 increased in the HepG2 and SSMC-7721 cells suggesting that Skp2-mediated degradation of p27kip1 was important for proliferation of the tumor cells.

Discussion

Hepatocellular carcinoma is the fifth most common type of malignant tumor worldwide and the third most common cause of cancer-associated death (34,35). Investigating the
variation in ongenes and suppressor genes during hepatocarcinogenesis assists in identifying the prognostic markers of the disease. Regulators controlling the cell cycle, including the G1, S and M phases, regulate the progression and development of several types of cancer, including liver cancer (36,37). The present study investigated the clinical predictive value of altered expression levels of p27kip1 and Skp2 in hepatocellular carcinoma tissues compared with normal liver tissues. The results revealed higher expression levels of Skp2, often accompanied by lower expression levels of p27kip1 in hepatocellular carcinoma, which suggested that they may be important in the pathogenesis and progression of liver cancer.

Skp2 is an F-box substrate-recognition subunit in the SCF ubiquitin-protein ligase complex, which is important in degrading the tumor suppressor gene p27kip1 by the ubiquitin-proteasome system (38-42). The present study demonstrated that the expression of p27kip1 was negatively associated with that of Skp2, which was detected by immunohistochemical and western blot analysis. Additionally, the results also demonstrated that interference of Skp2 by Skp2-siRNA significantly inhibited the proliferation of the HepG2 and SMMC-7721 cells, which was detected using an MTT assay and FACS analysis. Decreased levels of Skp2 are usually accompanied by increased levels of p27kip1, which are considered to be associated with the inhibition of cancer cells (43,44). The results of the present study demonstrated that inhibition of hepatocellular carcinoma by interference of Skp2 was mainly dependent on upregulating the protein expression of p27kip1.

P27kip1 degradation is mediated mainly by the ubiquitin-proteasome system and Skp2 is an E3 ligase, one of the major components of the SCF complex. This system specifically recognizes the phosphorylated Thr187 of p27kip1 and promotes the degradation of p27kip1 by ubiquination (30,45). When the protein levels of Skp2 decrease, less p27kip1 is recognized and degraded. Thus, accumulation of the tumor inhibitor protein p27kip1 is accompanied by downregulation of Skp2, which was consistent with the results of the MTT and FACS assays in the present study.

In conclusion, the present study confirmed increased expression of Skp2 accompanied by decreased expression of p27kip1 in hepatocellular carcinoma, with the two proteins having a negative correlation. Additionally, the RNA interference technique may provide a novel approach for the therapy and treatment of liver carcinoma.

References


